Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Among all mental disorders, major depression has the highest rate of prevalence and incidence of morbidity. Currently available antidepressant therapies have limited efficacies; consequently, research on new drugs for the treatment of mood disorders has become increasingly critical. Recent preclinical evidences that cannabinoid agonists and endocannabinoid enhancers, such as the fatty acid amide hydrolase (FAAH) inhibitors, can impact mood regulation have opened a new line of research in antidepressant drug discovery. However, the neurobiological mechanisms linking the endocannabinoid system with the pathophysiology of mood disorders and antidepressant action remain unclarified. In this review, we have presented an update on preclinical data indicating the antidepressant potential of cannabinoid agonists and endocannabinoid enhancers in comparison to standard antidepressants. Data obtained from CB(1) knockout (CB(1)-/-) and FAAH knockout (FAAH-/-) mice have also been examined within this context. We have illustrated how the various classes of antidepressants exert their therapeutic action. In particular, all antidepressants increase the neurotransmission of serotonin after long-term treatment, enhance the tonic activity of hippocampal 5-HT(1A) receptors, promote neurogenesis, and modulate (decrease or increase) the firing activity of noradrenergic neurons. Interestingly, cannabinoid agonists and endocannabinoid enhancers increase serotonin and noradrenergic neuronal firing activity, increase serotonin release in the hippocampus, as well as promote neurogenesis. Since cannabinoid-derived drugs potentiate monoaminergic neurotransmission and hippocampal neurogenesis through distinct pathways compared to classical antidepressants, they may represent an alternative drug class in the pharmacotherapy of mood and other neuropsychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534 · cited 1×
“The TST operates on the phenomenon that antidepressants, regardless of mechanism of action, reverse or delay the immediate transition of active escape-oriented behaviours into passive immobility in mice suspended by the tail from a lever [137].”
BackgroundBehavioural despair in rats: A new model sensitive to antidepressant treatments
Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“Anandamide and 2-AG were the first eicosanoid-derived endocannabinoids to be discovered and characterized [54, 55].”
BackgroundInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 2×
“CB1 density was determined to be much lower in the diencephalon (thalamus and hypothalamus), area postrema and the midbrain, and essentially null in the medulla [32, 33].”
BackgroundNibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109
Cryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674
Willner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · cited 2×
“Exposing rodents to chronic unpredictable mild stressors (CMS) possesses high degrees of face, construct and predictive validities as a behavioural paradigm since it mimics from the human milieu the role of stress in the etiology of depressive disorders; the efficacy of long-term but not shortterm antidepressant treat…”
BackgroundImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 2×
“CB1 density was determined to be much lower in the diencephalon (thalamus and hypothalamus), area postrema and the midbrain, and essentially null in the medulla [32, 33].”
BackgroundThe orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · cited 1×
“In fact, the novel putative non-CB1/CB2 receptor GPR55 was found to be coupled to Gq and G12, characteristically distinct from CB1 and CB2 intracellular coupling, and are activated by various cannabinoid agonists [17, 232].”
BackgroundIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
The ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198 · cited 3×
“One may readily attribute these discrepancies to the standard FST protocol in mice involving just a single swim exposure [99-101]; it may unlikely yield equally meaningful information about “learned despair” as compared to the rat FST.”
BackgroundEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Course of illness, hippocampal function, and hippocampal volume in major depression
MacQueen, G. M., Campbell, S., McEwen, B. S., Macdonald, K., Amano, S., Joffe, R. T., Nahmias, C., & Young, L. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337481100 · Cited by 980
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Self-citationMann, J. J., Huang, Y.-Y., Underwood, M. D., Kassir, S. A., Oppenheim, S., Kelly, T. M., Dwork, A. J., & Arango, V. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.729 · Cited by 613
Johansen-Berg, H., Gutman, D. A., Behrens, T. E. J., Matthews, P. M., Rushworth, M. F. S., Katz, E., Lozano, A. M., & Mayberg, H. S. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm167 · Cited by 561
Jiang, W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25509 · Cited by 527 · cited 7×
“The CB1 agonists HU-210 [104, 105], CP55,940 [106], WIN55,212-2 [107], have all been shown to decrease immobility in the rat FST without modifying locomotor activity in the open field.”
BackgroundInfluentialLin, P.-Y., & Su, K.-P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0712 · Cited by 481
Hippocampal volume, memory, and cortisol status in major depressive disorder: Effects of treatment
Vythilingam, M., Vermetten, E., Anderson, G. M., Luckenbaugh, D., Anderson, E. R., Snow, J., Staib, L. H., Charney, D. S., & Bremner, J. D. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.04.002 · Cited by 477
The effects of chronic antidepressant treatment in an animal model of anxiety
Bodnoff, S., Suranyi-Cadotte, B., Aitken, D., Quirion, R., & Meaney, M. (1988) · Psychopharmacology · doi:10.1007/bf00181937 · Cited by 437 · cited 1×
“Acute treatment of anxiolytics, as well as chronic treatment with conventional antidepressants, have been demonstrated to decrease the latency to feed in the novel environment, while feeding latency in the familiar home cage environment does not differ between drug-treated and control animals [147].”
BackgroundFegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Self-citationEffect of vagus nerve stimulation on serotonergic and noradrenergic transmission
Dorr, A. E., & Debonnel, G. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104166 · Cited by 420
High-speed imaging reveals neurophysiological links to behavior in an animal model of depression
Airan, R. D., Meltzer, L. A., Roy, M., Gong, Y., Chen, H., & Deisseroth, K. (2007) · Science · doi:10.1126/science.1144400 · Cited by 396 · cited 1×
“A recent study found that although inhibiting rat hippocampal neurogenesis by irradiation was neither sufficient nor required in inducing depression-like behaviours (increased immobility) in the forced swim test, it is nonetheless required for the antidepressant-like effect (decreased immobility) of fluoxetine to ensu…”
BackgroundHill, M. N., Patel, S., Carrier, E. J., Rademacher, D. J., Ormerod, B. K., Hillard, C. J., & Gorzalka, B. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300601 · Cited by 363 · cited 1×
“CMS was associated with a progressive reduction in the activity of the endocannabinoid system that is characterized by increased prefrontocortical CB1 mRNA and decreased midbrain CB1 mRNA [76, 162], decreased hippocampal 2-AG levels [162, 163], a widespread decrease in anandamide levels, increased prefrontocortical CB…”
BackgroundThe effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354 · cited 1×
“These receptors, as well as other yet unidentified ones, might therefore participate in the central and psychotropic effects of cannabinoids that are preserved in transgenic mice lacking CB1 [18-20].”
BackgroundEgertová, M., Cravatt, B. F., & Elphick, M. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00145-3 · Cited by 347 · cited 1×
“Therefore, URB597 and URB602 can only modulate CB1 function via elevated endocannabinoid levels in select brain regions that express postsynaptic FAAH or MGL in close proximity to presynaptic CB1 [72-74] and that are actively releasing endocannabinoids.”
BackgroundBambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325 · cited 10×
“For example, within a dose range that did not influence locomotor activity, WIN55,212-2 [107] and CP55,940 [106] decreased immobility only at low doses.”
BackgroundInfluentialSelf-citationHaller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241 · cited 3×
“These receptors, as well as other yet unidentified ones, might therefore participate in the central and psychotropic effects of cannabinoids that are preserved in transgenic mice lacking CB1 [18-20].”
BackgroundRademacher, D. J., Meier, S. E., Shi, L., Vanessa Ho, W.-S., Jarrahian, A., & Hillard, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.012 · Cited by 233 · cited 1×
“3 mg/kg, intraperitoneal) in mice subjected to repeated restraint stress resulted in an antidepressant-like blockade of stress-induced anhedonia when tested after 1, 4 and 7 days but not after 10 days of stress, while rimonabant (1 mg/kg, intraperitoneal) enhanced anhedonia-like response [160, 161].”
BackgroundEvaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184 · cited 5×
“FAAH-/- mice (C57BL/6J) immobility [130]”
MethodResultInfluentialRusso, R., LoVerme, J., La Rana, G., Compton, T. R., Parrott, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119941 · Cited by 182
Self-citationMcGregor, I. S., Callaghan, P. D., & Hunt, G. E. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.132 · Cited by 171
Daban, C., Martinez-Aran, A., Cruz, N., & Vieta, E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.02.012 · Cited by 163
Patel, S., & Hillard, C. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06266.x · Cited by 162 · cited 2×
“These changes were interpreted as a unique adaptive response of the endocannabinoid system to repeated homotypic stress [162].”
BackgroundBidirectional cannabinoid modulation of social behavior in adolescent rats
Trezza, V., & Vanderschuren, L. J. M. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1025-3 · Cited by 159 · cited 1×
“Acute and chronic administration of direct CB1 agonists, including 9 -THC [65, 151], CP55,940 [152] and WIN55,212-2 [153, 154], reduce many aspects of social behaviour, such as social exploration/investigation, social grooming and aggressiveness.”
Background
Cited by
Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects
Mahar, I., Bambico, F. R., Mechawar, N., & Nobrega, J. N. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.009 · Cited by 694
Self-citationDeiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Arthur, M., Fleming, S., Woodcock, H., Dorward, P., Pigliacampo, B., Close, S., et al. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2415-0 · Cited by 398
Degenhardt, L., Coffey, C., Romaniuk, H., Swift, W., Carlin, J. B., Hall, W. D., & Patton, G. C. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04015.x · Cited by 237
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Bambico, F. R., Nguyen, N.-T., Katz, N., & Gobbi, G. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.020 · Cited by 161
Self-citation
Metadata
- Authors
- Rodriguez Bambico, F., Duranti, A., Tontini, A., Tarzia, G., & Gobbi, G.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-05-01
- Volume
- 15
- Issue
- 14
- Pages
- 1623-1646
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2011337772
- Cited by
- 91
- References
- 41
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.